Fulcrum Therapeutics, Inc. (FULC)
3.86
+0.02
(+0.52%)
USD |
NASDAQ |
Aug 25, 16:00
3.83
-0.03
(-0.78%)
After-Hours: 19:59
Fulcrum Therapeutics Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 69.26% |
| March 31, 2024 | |
| December 31, 2023 | -2.84K% |
| September 30, 2023 | -3.16K% |
| June 30, 2023 | -2.70K% |
| March 31, 2023 | -8.40K% |
| December 31, 2022 | -3.82K% |
| September 30, 2022 | -2.01K% |
| June 30, 2022 | -1.81K% |
| Date | Value |
|---|---|
| March 31, 2022 | -1.00K% |
| December 31, 2021 | -464.3% |
| September 30, 2021 | -419.8% |
| June 30, 2021 | -448.5% |
| March 31, 2021 | -355.0% |
| December 31, 2020 | -419.4% |
| September 30, 2020 | -1.03K% |
| June 30, 2020 | -784.2% |
| March 31, 2020 | -2.46K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -3.01K% |
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 67.84% |
| Definium Therapeutics, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -30.23% |
| Return on Assets | -28.70% |
| Return on Invested Capital | -29.56% |
| Return on Net Operating Assets | -914.1% |